Table 2.
Methyltransferase | Histone site | Interventions | Experimental model | Results | Ref. |
---|---|---|---|---|---|
DOT1L | H3K79me2 | EPZ5676 | UUO | TGF-β↓, G2/M arrest↓, Snail↓, Twist↓, Notch↓, SMAD3↓, EGFR↓, PDGFR↓, STAT3↓, AKT↓, NF-κB↓, KLOTHO↑, SMAD7↑ | 289 |
H3K79 | EPZ004777 | IRI | ROS↓, PI3K/AKT↓ | 290 | |
G9a | H3K9me1 | BIX01294 | UUO | α-SMA↓, fibronectin↓, KLOTHO↑ | 291 |
SMYD2 | H3K36me3 | AZ505 | UUO | SMAD3↓, ERK1/2↓, AKT↓, STAT3↓, NF-kB↓, Snail↓, Twist↓, SMAD7↑ | 292 |
SETD7 | H3K4 | PFI-2 | folic acid, UUO | M2 macrophages-myofibroblasts transition↓, myeloid fibroblasts activation↓, inflammation↓ | 293 |
H3K4me1 | sinefungin | UUO | mesenchymal markers↓, ECM↓ | 294 | |
H3K4me2 | - | type 1 diabetes (STZ) | Col1a↑ | 295 | |
SUV39H1 | H3K9me2 | - | type 1 diabetes (STZ) | Col1a↑ | 295 |
EZH2 | H3k27me3 | 3-DZNeP, GSK126 | UUO | SMAD7↑, PTEN↑ | 296 |
H3k27me3 | 3-DZNeP | hyperuricemia | serum uric acid↓, XOD↓, TGF-β/Smad3↓, EGFR↓, ERK1/2↓, EMT↓, apoptosis↓, fibroblast activation↓, ECM↓, NF-κB↓ | 297 | |
H3k27me3 | GNA | UUO, folic acid | Smad7↑, TGF-β/Smad3↓, α-SMA↓, fibronectin↓, collagens↓ | 298 | |
PRMT1 | H4R3Me2a | AMI-1 | UUO | TGF-β/Smad3↓ | 299 |
MLL1/WDR5 | H3K4me3 | MM-102, OICR-9429 | IRI | p16↓ | 300 |
AKT protein kinase B, α-SMA alpha-smooth-muscle actin, Col1a collagen-1α, DOT1L disruptor of telomeric silencing 1-like, ECM extracellular matrix, EGFR epidermal growth factor receptor, EMT epithelial-to-mesenchymal transition, ERK extracellular signal-regulated kinase, EZH2 enhancer of zester homolog 2, GNA gambogenic acid, IRI ischemia-reperfusion injury, MLL1 mixed-lineage leukemia 1, NF-κB nuclear factor kappa B, PI3K phosphatidylinositol 3-kinase, PDGFR platelet-derived growth factor receptor, PRMT-1 protein arginine methyltransferase 1, PTEN phosphatase and tensin homolog, ROS reactive oxygen species, STED7 SET domain containing 7 histone lysine methyltransferase, SMYD2 SET and MYND domain containing 2, STAT3 signal transducer and activator of transcription 3, STZ streptozotocin, TGF-β transforming growth factor beta, UUO unilateral ureteral occlusion, WDR5 WD repeat domain 5, XOD xanthine oxidase, 3-DZNeP 3-deazaneplanocin A